Full-Time

Thought Leader Liaison

Pharvaris

Pharvaris

51-200 employees

Develops oral bradykinin B2 antagonists

Compensation Overview

$170k - $200k/yr

+ Equity + Sales incentives

Remote in USA

Remote

Candidates must be based within their applicable zone geography.

Bachelor's, Master's

Category
Business & Strategy (1)
Required Skills
Branding/Brand Strategy
Marketing

Get referred to Pharvaris

See people who can refer or advise you

Requirements
  • A bachelor's degree is required.
  • At least 8 years of commercial experience in biotechnology or pharmaceuticals, including at least 1 year in thought leader engagement, field marketing, or a related role.
  • The ability to generate, synthesize, and communicate insights that inform brand and commercial strategy.
  • Experience working effectively in matrixed organizations and navigating ambiguity.
  • Strong interpersonal, communication, and presentation skills.
  • Comfort operating in a fast-paced, entrepreneurial environment requiring strategic thinking and hands-on execution.
Responsibilities
  • Develop and maintain key opinion leader engagement plans to map influence and drive advocacy.
  • Plan and execute a congress engagement plan focused on meaningful engagements with senior leadership and support for marketing initiatives.
  • Build and sustain relationships with local, regional, and national thought leaders, including key opinion leaders, academic investigators, and influential healthcare professionals involved in the diagnosis, treatment, and advocacy of hereditary angioedema.
  • Maintain significant customer-facing time to proactively engage thought leaders in current and future commercial initiatives.
  • Generate actionable insights through structured and unstructured engagements with thought leaders.
  • Translate field insights into timely recommendations for stakeholders across Marketing, Sales, Market Access, Patient Services, and Commercial Strategy.
  • Support national, regional, and local insight reporting to align the organization with the overarching Thought Leader Development strategy.
  • Collaborate with Medical Affairs, Research and Development, Market Access, Patient Services, Sales, Training, and Marketing to address customer needs, identify projects of mutual interest, anticipate market trends, and surface competitive intelligence.
  • Adhere to guidelines governing commercial and medical interactions and connect thought leaders with Medical Affairs or Research and Development for clinical or scientific discussions as needed.
  • Support the development and execution of advisory council engagements with field and marketing partners.
  • Partner with Marketing to support speaker training initiatives and development of the United States Speaker Bureau.
  • Lead ongoing training and coaching for speakers to ensure mastery of approved materials and consistent delivery of high-value education.
  • Participate in the design, development, and execution of advisory boards, including moderating discussions and facilitating dialogue.
  • Incorporate thought leader insights into content development to improve the relevance, impact, and strategic alignment of programs.
  • Identify and initiate compliant programs or tactical opportunities that deliver value to the company and external experts.
  • Support commercial fee-for-service engagements and needs assessments aligned with company objectives.
  • Collaborate with Legal, Regulatory, and Compliance partners to ensure compliant execution of activities.
  • Contribute to annual thought leader liaison planning activities, including territory strategy and prioritization.
  • Execute projects with discipline, follow-through, and ownership in a startup environment.
Desired Qualifications
  • An advanced degree such as a Master of Business Administration or Master of Public Health.
  • Launch experience, ideally in rare disease, immunology, or specialty therapeutics.

Pharvaris develops oral medications aimed at treating hereditary angioedema (HAE) and other bradykinin B2 receptor–mediated conditions. Its main focus is discovery and development of novel oral bradykinin B2 receptor antagonists that patients can take by mouth rather than by injection. The products work by blocking the bradykinin B2 receptor, which helps reduce or prevent swelling associated with these rare disorders. This approach sets Pharvaris apart from many current therapies that require injections, offering a convenient alternative for patients. The company operates in the clinical-stage biopharmaceutical space, pursuing regulatory approval and eventual commercialization of its oral therapies. Pharvaris’ goal is to provide effective, easier-to-use treatments that improve patient choice and quality of life for people with rare disease conditions.

Company Size

51-200

Company Stage

IPO

Headquarters

Leiden, Netherlands

Founded

2015

Get referred to Pharvaris

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • May 2026 financing lifted cash to €318 million, funding operations into 2028.
  • RAPIDe-3 and CHAPTER-1 presentations at AAAAI and ACAAI strengthened physician awareness in 2026.
  • If CHAPTER-3 succeeds, Pharvaris gains a differentiated oral franchise across HAE treatment settings.

What critics are saying

  • April 23, 2027 PDUFA can reject deucrictibant, leaving Pharvaris with no approved product.
  • CHAPTER-3 Q3 2026 readout can miss efficacy expectations and crush the oral-prophylaxis thesis.
  • €318 million cash and recurring losses burn runway if launch delays extend beyond 2028.

What makes Pharvaris unique

  • Deucrictibant targets both on-demand and prophylactic HAE with one oral bradykinin antagonist.
  • July 2026 FDA NDA acceptance and EMA validation separate Pharvaris from preclinical peers.
  • CHAPTER-1 and RAPIDe-3 data support injectable-like efficacy with oral convenience.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Flexible Work Hours

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

0%
Associated Press
Aug 12th, 2026
Pharvaris reports $359M cash position, deucrictibant Phase 3 data due in Q3 2026

Pharvaris, a late-stage biopharmaceutical company developing oral treatments for bradykinin-mediated angioedema, reported second quarter 2026 financial results. The company held €318 million in cash and cash equivalents as of 30 June 2026. The FDA is reviewing Pharvaris' New Drug Application for deucrictibant IR, with a PDUFA date of 23 April 2027. The EMA validated the marketing authorisation application in July 2026. Pharvaris expects topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for hereditary angioedema prophylaxis, in the third quarter of 2026. Enrolment continues in CREAATE, a pivotal study for acquired angioedema treatment. The company closed a $132 million underwritten offering in May, extending its cash runway into 2028. Second quarter loss was €47.8 million, with R&D expenses of €35.0 million and G&A expenses of €15.8 million.

AInvest Fintech Inc.
Jul 6th, 2026
Pharvaris NV - FDA sets PDUFA action date for Deucrictibant IR NDA as April 23, 2027.

Pharvaris NV - FDA sets PDUFA action date for Deucrictibant IR NDA as April 23, 2027. Monday, Jul 6, 2026 6:50 am ET 1min read The U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) action date of April 23, 2027, for the New Drug Application (NDA) of deucrictibant immediate-release (IR) for the on-demand treatment of hereditary angioedema (HAE) attacks. This date marks the target by which the FDA aims to complete its review of the application, which is expected to be submitted in the first half of 2026. Pharvaris, a late-stage biopharmaceutical company, has been preparing the NDA dossier based on data from the RAPIDe-3 and RAPIDe-2 trials. The RAPIDe-3 study, a pivotal global Phase 3 trial, demonstrated that deucrictibant IR met its primary endpoint, with median time to onset of symptom relief of 1.28 hours, significantly faster than placebo. The company also plans to present additional data from these trials at upcoming medical congresses. The NDA filing is part of Pharvaris' broader strategy to commercialize deucrictibant for both on-demand and prophylactic treatment of HAE attacks. The company remains on track to submit the NDA in 1H2026, with clear timeline for regulatory review provided by the PDUFA date. Pharvaris also continues to advance its clinical development programs, including the ongoing CREAATE study for AAE-C1INH and the CHAPTER-3 trial for long-term prophylaxis of HAE attacks, with topline data expected in the third quarter of 2026. The company's cash runway extends into the first half of 2027, supporting its current development and commercialization efforts. The FDA's action date reflects the agency's prioritization of the application and provides a key milestone for Pharvaris as it moves toward potential regulatory approval and market launch of deucrictibant IR for HAE.

StockTitan
May 8th, 2026
Pharvaris prices $115M underwritten offering of 3.9M ordinary shares at $29.68

Pharvaris has priced an underwritten offering of 3,874,664 ordinary shares at $29.68 per share, expecting gross proceeds of approximately $115 million before underwriting discounts and commissions. The biopharmaceutical company has granted underwriters a 30-day option to purchase an additional 581,199 shares. The late-stage company is developing oral bradykinin B2 receptor antagonists for bradykinin-mediated diseases including hereditary angioedema and acquired angioedema due to C1 inhibitor deficiency. Morgan Stanley, Leerink Partners, Cantor and Wells Fargo Securities are acting as joint book-running managers. The offering is expected to close around 11 May 2026, subject to customary closing conditions. Shares are being offered through an effective shelf registration statement filed with the US Securities and Exchange Commission.

Yahoo Finance
Apr 30th, 2026
Pharvaris director sells $213K in shares under pre-planned trading arrangement

A director at Pharvaris N.V. sold 7,100 shares worth approximately $213,000 through a pre-scheduled Rule 10b5-1 trading plan, according to an SEC filing. The sale represents just 1.8% of director Johannes Schikan's direct holdings, leaving him with 388,067 shares valued at around $10.59 million. The transaction marks Schikan's only sale in the past year and was executed under a pre-arranged plan, indicating planned liquidity management rather than a change in outlook. No indirect holdings or derivative securities were involved in the transaction. Pharvaris, valued at $1.87 billion, is a clinical-stage biopharmaceutical company developing oral therapies for hereditary angioedema. The company's pipeline includes PHA121, PHVS416 and PHVS719, targeting various treatment approaches for the rare disease.

Associated Press
Apr 2nd, 2026
Pharvaris completes CHAPTER-3 enrollment with $330M cash, NDA submission on track for 1H2026

Pharvaris, a late-stage biopharmaceutical company developing oral treatments for bradykinin-mediated diseases, reported cash and cash equivalents of €292 million as of 31 December 2025. The company completed enrollment in CHAPTER-3, a pivotal study of deucrictibant XR for prophylactic treatment of hereditary angioedema attacks, with topline data expected in third quarter 2026. Pharvaris remains on track to submit a New Drug Application for deucrictibant IR for on-demand treatment of HAE attacks in first half 2026, following positive Phase 3 RAPIDe-3 results. The study demonstrated symptom relief in 1.28 hours and complete resolution in 11.95 hours. Full-year 2025 loss was €176 million, or €2.97 per share, compared to €134 million in 2024. Research and development expenses rose to €124 million from €98.6 million year-over-year.